from ihub re 13d Snippet 1 from Cytodyn Share
Post# of 155269
(Total Views: 840)
Posted On: 07/31/2021 2:57:01 AM
from ihub re 13d
Snippet 1 from Cytodyn Shareholder Community Group on FB:
DATE: JULY 28, 2021
TO: THE PAUL ROSENBAUM GROUP
(Name of Registrant as Specified in Its Charter)
PAUL A. ROSENBAUM
JEFFREY P. BEATY
ARTHUR L. WILMES
THOMAS J. ERRICO, M.D.
BRUCE PATTERSON, M.D.
PETER STAATS, M.D., MBA
MELISSA YEAGER
CCTV PROXY GROUP, LLC
FROM: CONCERNED SHAREHOLDERS
SUBJECT: POTENTIAL FAILURE TO DISCLOSE MATERIAL INFORMATION
The Schedule 13D must be filed within 10 days after the acquisition and must include certain key information, including the purpose of the acquisition. Specifically, Item 4 of Schedule 13D requires the filer to describe any proposals which relate to, among other things, (a) an extraordinary corporate transaction involving the issuer, such as a merger, (b) a sale of a material amount of assets of the issuer, (c) any change to the board of directors of the issuer and (d) any other material change to the issuer’s business or corporate structure.
Shareholders are concerned that the filings to date (13D, 14A) submitted by The Paul Rosenbaum Group (GROUP) to the SEC may contain numerous omissions and, therefore, present material misrepresentations of facts based on prior discussions, communications and commitments made to shareholders and others. NOTE: WE DO NOT KNOW OF, NOR ARE WE MAKING ANY ASSUMPTIONS OF, ANY WRONGDOING OR IMPROPER ACTIONS OR INACTIONS OF THE GROUP. WE SIMPLY WANT TO UNDERSTAND THE GROUP’S PLAN SO THAT SHAREHOLDERDS CAN BE INFORMED.
Please see the following References:
(1) Numerous emails and phone conversations with select shareholders occurring between March 1, 2021 – June 30, 2021.
(2) The Zoom conference call presentation and discussion by Paul Rosenbaum, Bruce Patterson, and others to discuss their plan for taking over the company. This Zoom meeting was held on May 6, 2021.
(3) Zoom Follow Up email from Paul Rosenbaum dated May 6, 2021:
Forwarded message
From: Paul R
Date: Thu, May 6, 2021 at 8:52 PM
Subject: Please make checks payable to CCTV ( Cytodyn Committee to Victory) for $7500
To:
To All:
Thanks for today. I think it was a productive meeting.
As I mentioned before, the checks will not be deposited in an account until we reach our stated goals both for funds needed, and shares required.
I must receive the checks immediately in order to meet our filing requirements
Please call if you have any additional questions
Thanking you in advance for your cooperation
Paul R
Make checks payable to CCTV for $7500.
Paul Rosenbaum
2945 NW Luray Terrace
Portland Oregon 97210
(4) Paul Rosenbaum’s letter of Concern to CytoDyn’s Board of Directors, specifically Section BASIS FOR SHAREHOLDER CONCERN, paragraph 3, which reads as follows:
3. Dismissal of Highly Credible Clinical Partners. There is no doubt that the research and public presentations by IncellDx and Bruce Patterson, MD, have raised CYDY’s public profile and increased its credibility. The circumstances surrounding the breakdown of the relationship between CYDY and IncellDx remain murky, but the results of the breakdown are apparent. IncellDx was a material source of scientific direction and Mechanism of Action (MOA) definition for CYDY. The elimination of this relationship appears to have resulted in a reduced understanding of how Leronlimab works and where drug development research should be focused.
(5) Letter to Dr. Pourhassan from Paul Rosenbaum and other shareholders representing over 175MM shares of stock. See Attachment #1: Letter to Dr. Pourhassan for the complete contents of the letter.
Excerpts:
…we are writing you on behalf of CytoDyn shareholders representing over 175MM shares of common stock and growing.
…The signatures below represent only a portion of the commitment to this position.
…Please do not underestimate our dedication to what is in the best interest of the shareholders.
…An IncellDx investor informed us that IncellDx was NOT involved in the combination therapy trial, and only became involved in the later stages of the mono-therapy trial.
…IncellDx has been leading the way in long hauler research and treatment. We have third party opinions that the IncellDx quantitative CCR5 IHC assay with a scoring system that can be followed, is far superior to what is available on the market today for CCR5 IHC.
Snippet 1 from Cytodyn Shareholder Community Group on FB:
DATE: JULY 28, 2021
TO: THE PAUL ROSENBAUM GROUP
(Name of Registrant as Specified in Its Charter)
PAUL A. ROSENBAUM
JEFFREY P. BEATY
ARTHUR L. WILMES
THOMAS J. ERRICO, M.D.
BRUCE PATTERSON, M.D.
PETER STAATS, M.D., MBA
MELISSA YEAGER
CCTV PROXY GROUP, LLC
FROM: CONCERNED SHAREHOLDERS
SUBJECT: POTENTIAL FAILURE TO DISCLOSE MATERIAL INFORMATION
The Schedule 13D must be filed within 10 days after the acquisition and must include certain key information, including the purpose of the acquisition. Specifically, Item 4 of Schedule 13D requires the filer to describe any proposals which relate to, among other things, (a) an extraordinary corporate transaction involving the issuer, such as a merger, (b) a sale of a material amount of assets of the issuer, (c) any change to the board of directors of the issuer and (d) any other material change to the issuer’s business or corporate structure.
Shareholders are concerned that the filings to date (13D, 14A) submitted by The Paul Rosenbaum Group (GROUP) to the SEC may contain numerous omissions and, therefore, present material misrepresentations of facts based on prior discussions, communications and commitments made to shareholders and others. NOTE: WE DO NOT KNOW OF, NOR ARE WE MAKING ANY ASSUMPTIONS OF, ANY WRONGDOING OR IMPROPER ACTIONS OR INACTIONS OF THE GROUP. WE SIMPLY WANT TO UNDERSTAND THE GROUP’S PLAN SO THAT SHAREHOLDERDS CAN BE INFORMED.
Please see the following References:
(1) Numerous emails and phone conversations with select shareholders occurring between March 1, 2021 – June 30, 2021.
(2) The Zoom conference call presentation and discussion by Paul Rosenbaum, Bruce Patterson, and others to discuss their plan for taking over the company. This Zoom meeting was held on May 6, 2021.
(3) Zoom Follow Up email from Paul Rosenbaum dated May 6, 2021:
Forwarded message
From: Paul R
Date: Thu, May 6, 2021 at 8:52 PM
Subject: Please make checks payable to CCTV ( Cytodyn Committee to Victory) for $7500
To:
To All:
Thanks for today. I think it was a productive meeting.
As I mentioned before, the checks will not be deposited in an account until we reach our stated goals both for funds needed, and shares required.
I must receive the checks immediately in order to meet our filing requirements
Please call if you have any additional questions
Thanking you in advance for your cooperation
Paul R
Make checks payable to CCTV for $7500.
Paul Rosenbaum
2945 NW Luray Terrace
Portland Oregon 97210
(4) Paul Rosenbaum’s letter of Concern to CytoDyn’s Board of Directors, specifically Section BASIS FOR SHAREHOLDER CONCERN, paragraph 3, which reads as follows:
3. Dismissal of Highly Credible Clinical Partners. There is no doubt that the research and public presentations by IncellDx and Bruce Patterson, MD, have raised CYDY’s public profile and increased its credibility. The circumstances surrounding the breakdown of the relationship between CYDY and IncellDx remain murky, but the results of the breakdown are apparent. IncellDx was a material source of scientific direction and Mechanism of Action (MOA) definition for CYDY. The elimination of this relationship appears to have resulted in a reduced understanding of how Leronlimab works and where drug development research should be focused.
(5) Letter to Dr. Pourhassan from Paul Rosenbaum and other shareholders representing over 175MM shares of stock. See Attachment #1: Letter to Dr. Pourhassan for the complete contents of the letter.
Excerpts:
…we are writing you on behalf of CytoDyn shareholders representing over 175MM shares of common stock and growing.
…The signatures below represent only a portion of the commitment to this position.
…Please do not underestimate our dedication to what is in the best interest of the shareholders.
…An IncellDx investor informed us that IncellDx was NOT involved in the combination therapy trial, and only became involved in the later stages of the mono-therapy trial.
…IncellDx has been leading the way in long hauler research and treatment. We have third party opinions that the IncellDx quantitative CCR5 IHC assay with a scoring system that can be followed, is far superior to what is available on the market today for CCR5 IHC.
(8)
(0)